Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.03
MYGN's Cash-to-Debt is ranked lower than
69% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. MYGN: 1.03 )
Ranked among companies with meaningful Cash-to-Debt only.
MYGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.75  Med: No Debt Max: No Debt
Current: 1.03
Equity-to-Asset 0.59
MYGN's Equity-to-Asset is ranked lower than
55% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. MYGN: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
MYGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.57  Med: 0.89 Max: 0.96
Current: 0.59
0.57
0.96
Interest Coverage 16.56
MYGN's Interest Coverage is ranked lower than
56% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. MYGN: 16.56 )
Ranked among companies with meaningful Interest Coverage only.
MYGN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: 16.56
Piotroski F-Score: 4
Altman Z-Score: 2.40
Beneish M-Score: -3.41
WACC vs ROIC
2.91%
4.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 8.97
MYGN's Operating Margin % is ranked higher than
75% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. MYGN: 8.97 )
Ranked among companies with meaningful Operating Margin % only.
MYGN' s Operating Margin % Range Over the Past 10 Years
Min: -30.37  Med: 35.81 Max: 39.24
Current: 8.97
-30.37
39.24
Net Margin % 4.25
MYGN's Net Margin % is ranked higher than
80% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. MYGN: 4.25 )
Ranked among companies with meaningful Net Margin % only.
MYGN' s Net Margin % Range Over the Past 10 Years
Min: -22.25  Med: 22.63 Max: 42
Current: 4.25
-22.25
42
ROE % 4.31
MYGN's ROE % is ranked higher than
66% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. MYGN: 4.31 )
Ranked among companies with meaningful ROE % only.
MYGN' s ROE % Range Over the Past 10 Years
Min: -11.85  Med: 18.28 Max: 30.71
Current: 4.31
-11.85
30.71
ROA % 2.89
MYGN's ROA % is ranked higher than
76% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. MYGN: 2.89 )
Ranked among companies with meaningful ROA % only.
MYGN' s ROA % Range Over the Past 10 Years
Min: -10.72  Med: 16.98 Max: 28.73
Current: 2.89
-10.72
28.73
ROC (Joel Greenblatt) % 50.18
MYGN's ROC (Joel Greenblatt) % is ranked higher than
87% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. MYGN: 50.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MYGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -199.02  Med: 251.31 Max: 362.64
Current: 50.18
-199.02
362.64
3-Year Revenue Growth Rate 11.70
MYGN's 3-Year Revenue Growth Rate is ranked higher than
71% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. MYGN: 11.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MYGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 1.6  Med: 20.65 Max: 45.7
Current: 11.7
1.6
45.7
3-Year EBITDA Growth Rate -2.50
MYGN's 3-Year EBITDA Growth Rate is ranked lower than
59% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. MYGN: -2.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MYGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -10.2  Med: 7.6 Max: 48.5
Current: -2.5
-10.2
48.5
3-Year EPS without NRI Growth Rate -1.10
MYGN's 3-Year EPS without NRI Growth Rate is ranked lower than
51% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. MYGN: -1.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MYGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -17.1  Med: 3.6 Max: 68.8
Current: -1.1
-17.1
68.8
GuruFocus has detected 7 Warning Signs with Myriad Genetics Inc $MYGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MYGN's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

MYGN Guru Trades in Q2 2016

Lee Ainslie 93,870 sh (New)
First Eagle Investment 368,980 sh (New)
Joel Greenblatt 360,830 sh (+79.05%)
Jim Simons 1,332,300 sh (+28.75%)
Ken Fisher 92,236 sh (+2.73%)
Mario Gabelli 25,000 sh (unchged)
RS Investment Management Sold Out
Chuck Royce 937,498 sh (-27.03%)
Paul Tudor Jones 14,167 sh (-36.73%)
» More
Q3 2016

MYGN Guru Trades in Q3 2016

Ron Baron 40,000 sh (New)
Paul Tudor Jones 31,742 sh (+124.06%)
Jim Simons 2,931,674 sh (+120.05%)
Lee Ainslie 152,050 sh (+61.98%)
Joel Greenblatt 421,728 sh (+16.88%)
Ken Fisher 92,381 sh (+0.16%)
Mario Gabelli Sold Out
First Eagle Investment Sold Out
Chuck Royce 90,369 sh (-90.36%)
» More
Q4 2016

MYGN Guru Trades in Q4 2016

Ron Baron 80,000 sh (+100.00%)
Paul Tudor Jones 47,033 sh (+48.17%)
Lee Ainslie 190,720 sh (+25.43%)
Chuck Royce Sold Out
Jim Simons 2,686,174 sh (-8.37%)
Joel Greenblatt 289,042 sh (-31.46%)
Ken Fisher 59,731 sh (-35.34%)
» More
Q1 2017

MYGN Guru Trades in Q1 2017

Ron Baron 136,500 sh (+70.63%)
Joel Greenblatt 349,262 sh (+20.83%)
Ken Fisher 61,011 sh (+2.14%)
Lee Ainslie Sold Out
Paul Tudor Jones 19,700 sh (-58.11%)
Jim Simons 534,700 sh (-80.09%)
» More
» Details

Insider Trades

Latest Guru Trades with MYGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:NAS:FMI, NAS:VREX, NAS:AXDX, NAS:ABAX, NAS:MEDP, NAS:GHDX, NAS:KANG, NAS:ALOG, NAS:QDEL, NAS:BEAT, NAS:HSKA, NAS:NRCIA, NAS:LNTH, NAS:NEO, NAS:VIVO, NAS:NTRA, NYSE:ARA, NAS:NVDQ, NYSE:ENZ, NAS:NEOG » details
Traded in other countries:MYD.Germany,
Headquarter Location:USA
Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.

Myriad Genetics develops genetic diagnostic products. It is best known for its BRACAnalysis test, which assesses a woman's risk of developing hereditary breast and ovarian cancer. The company is transitioning its hereditary cancer tests to a single multigene panel, myRisk, which screens 25 genes across multiple cancer indications. Other products include Prolaris (prostate cancer) and other prognostic tests. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.

Top Ranked Articles about Myriad Genetics Inc

Medicare Coverage of Prolaris® Test Expands with the Addition of Men Diagnosed with Favorable Intermediate Risk Prostate Cancer
Myriad Genetics’ Prolaris® Test Accurately Predicts the 10-Year Risk of Metastases in Men Treated for Prostate Cancer
Myriad Genetics to Present Results from Four Studies at the American Urological Association 2017 Annual Meeting
Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) Treatment
Myriad to Announce Fiscal Third-Quarter 2017 Financial Results on May 2, 2017
Study Finds Wide Gap in Quality of BRCA1/2 Variant Classification Between Myriad Genetics and A Common Public Database
Myriad Genetics and BeiGene Sign Agreement to Develop Companion Diagnostics for Use with BeiGene’s Novel PARP Inhibitor, BGB-290
Pivotal Study Results for Myriad’s myPath® Melanoma Test Highlighted In Two Additional Scientific Publications
Myriad Genetics Announces Five Scientific Presentations at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting

New Data Will Highlight Advances in Genetic Variant Classification for Hereditary Cancers

SALT LAKE CITY, March 20, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the company will present five scientific posters at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting in Phoenix, AZ.  The presentations will highlight new data on variant classification and hereditary cancer syndromes.
“As genetic testing for hereditary cancer syndromes increases, we are generating tremendous volumes of data and identifying new genetic variants every day.  Our highest priority is making sure patients and their families get accurate test results, which demands years of variant classification experience,” said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories.  “Myriad has been the leader in variant classification for more than 25 years, making us the most experienced commercial lab in the industry.  Our passion for helping patients continues, and we are very excited to be presenting five new cutting-edge studies at ACMG that advance the science of variant classification.” The poster abstracts are now available here.  Follow Myriad on Twitter via @MyriadGenetics to stay informed about news and updates from the Company. Featured Poster Presentations Title: A significant proportion of TP53 pathogenic variants detected with a hereditary pan-cancer NGS panel are somatically acquired. 
Date: Thursday, March 23, 2017: 10:00–11:30 a.m. MST. 
Location: Poster 173. 
Presenter: Bradford Coffee.

Title: Complexities in hereditary cancer variant classification: Three case examples. 
Date: Friday, March 24, 2017: 10:30 a.m.–12:00 p.m. MST. 
Location: Poster 154. 
Presenter: Erin Mundt.

Title: Case report: Sub-clinical Fanconi Anemia in siblings with bi-allelic BRIP1 mutations. 
Date: Friday, March 24, 2017: 10:30 a.m.–12:00 p.m. MST. 
Location: Poster 378. 
Presenter: Jamie Willmott.

Title: Prevalence and characterization of triplications in genes associated with hereditary cancers. 
Date: Friday, March 24, 2017: 10:30 a.m.–12:00 p.m. MST. 
Location: Poster 148. 
Presenter: Heather LaBreche.

Title: Apparent gene conversion event detected in CHEK2 using next generation sequencing analysis. 
Date: Friday, March 24, 2017: 10:30 a.m.–12:00 p.m. MST. 
Location: Poster 156. 
Presenter: Shujuan Pan.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Safe Harbor Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to statements related to data being presented at American College of Medical Genetics Annual Clinical Genetics Meeting; the presentation of new data highlighting variant classification and hereditary cancer syndromes; the volumes of data being generated by the Company and the daily identification of new genetic variants; and the Company’s strategic directives under the caption “About Myriad Genetics.”  These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

Media Contact:
Ron Rogers
(908) 285-0248
[email protected]

Investor Contact:
Scott Gleason
(801) 584-1143
[email protected]

Read more...
Myriad Genetics Launches the EndoPredict® Test in the United States for Patients with Breast Cancer

Second-Generation Test Provides More Accurate 10-Year Recurrence Risk for Patients Diagnosed with ER HER2- Early-Stage Breast Cancer

SALT LAKE CITY, March 13, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has launched the EndoPredict® test in the United States for patients with ER HER2- early-stage breast cancer.  EndoPredict is a second-generation test for assessing the 10-year risk of disease recurrence following surgery and for determining which patients can safely forgo adjuvant chemotherapy.
“Today’s launch strengthens our oncology product portfolio and represents a meaningful advancement in the treatment of patients with breast cancer,” said Lloyd Sanders, general manager, Oncology, Myriad Genetic Laboratories.  â€œAlong with our best-in-class tests for hereditary cancer and our companion diagnostics, the launch of EndoPredict underscores our commitment to pioneering science, personalized medicine and patient care.”  EndoPredict is supported by multiple prospective clinical studies and data from more than 3,500 patients with ER HER2- node negative and node positive early-stage breast cancer.  The results of the clinical development program show that EndoPredict substantially outperforms the first generation breast cancer recurrence tests.  EndoPredict was trained and validated using 10-year outcomes data and includes proliferation-related genes as well as hormone receptor-related genes, providing accurate assessment of early and late risk for recurrence and definitively classifies patients as low or high risk.  â€œBreast cancer is a complicated disease and there is a critical need for accurate breast cancer recurrence tests that help physicians determine which patients can safely forgo adjuvant chemotherapy,” said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories.  “The launch of EndoPredict is an important advancement for patients and doctors.  By automatically incorporating clinical features and generating an individualized patient test result, EndoPredict identifies a larger subset of true low-risk patients who may safely forgo adjuvant chemotherapy." EndoPredict already is included in medical guidelines including the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO) and the St. Gallen International Breast Conference.  Additionally, the Integrated Oncology Network (ION) named EndoPredict as its preferred breast cancer recurrence test.  Myriad is working with payers to making sure EndoPredict is a widely accessible to patients.  So far, the test has received positive coverage decisions from 19 payers, bringing total coverage to over 70 million patients in the United States. Follow Myriad on Twitter via @MyriadGenetics and stay informed about Company news and updates. Clinical Data Supporting the Launch  Name of Trial # of
Patients Breast Cancer
Sub-Type Nodal Status 10-Year Distant
Metastasis Rate
for Low Risk
GroupMulticenter964ER /HER2-NO, N 7.0%ABCSG-6378ER /HER2-NO, N 4.0%ABCSG-81,324ER /HER2-NO, N 4.0%ATAC928ER /HER2-NO, N 5.8% About Breast Cancer
Breast cancer is the second leading cause of mortality among women.  A woman living in the United States has a 12.3 percent, or a 1 in 8, lifetime risk of being diagnosed with breast cancer.  In 2017, invasive breast cancer will be diagnosed in more than 246,660 women. About EndoPredict
EndoPredict is a second-generation, multigene test designed to predict disease recurrence in patients diagnosed with breast cancer.  The test provides physicians with information to develop personalized treatment plans for their patients.  EndoPredict has been validated in approximately 3,500 patients with node-negative and node-positive cancer and has been used clinically in over 13,000 patients.  EndoPredict was trained and validated using 10-year outcomes data and includes proliferation-related genes as well as hormone receptor-related genes providing an accurate assessment of early and late risk for recurrence. Therefore, therapy decisions backed by EndoPredict confer a high level of diagnostic safety. For more information, please visit: www.endopredictusa.com. About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G. Safe Harbor Statement       
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the launch of the EndoPredict test in the United States for patients with ER HER2- early-stage breast cancer; the ability of EndoPredict to assess the 10-year risk of disease recurrence following surgery; the ability of EndoPredict to identify a larger subset of true low-risk patients who may safely forgo adjuvant chemotherapy;  EndoPredict providing more accurate 10-year risk for patients diagnosed with ER HER2- early-stage breast cancer;  the ability of EndoPredict to determine which patients can safely forgo adjuvant chemotherapy; EndoPredict substantially outperforming the first generation breast cancer recurrence tests; the extent of positive coverage decisions for EndoPredict and the Company’s work with payers to make sure EndoPredict is widely accessible to patients; therapy decisions backed by EndoPredict conferring a high level of diagnostic safety; and the Company’s strategic directives under the caption “About Myriad Genetics.”  These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
Media Contact:
Ron Rogers
(801) 584-3065
[email protected]

Investor Contact:
Scott Gleason
(801) 584-1143
[email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 45.13
MYGN's PE Ratio is ranked higher than
73% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. MYGN: 45.13 )
Ranked among companies with meaningful PE Ratio only.
MYGN' s PE Ratio Range Over the Past 10 Years
Min: 9.06  Med: 19.49 Max: 63.15
Current: 45.13
9.06
63.15
Forward PE Ratio 18.28
MYGN's Forward PE Ratio is ranked higher than
80% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. MYGN: 18.28 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 45.13
MYGN's PE Ratio without NRI is ranked higher than
74% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. MYGN: 45.13 )
Ranked among companies with meaningful PE Ratio without NRI only.
MYGN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.06  Med: 18.64 Max: 49.73
Current: 45.13
9.06
49.73
Price-to-Owner-Earnings 59.21
MYGN's Price-to-Owner-Earnings is ranked lower than
52% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. MYGN: 59.21 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MYGN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.71  Med: 23.8 Max: 115.39
Current: 59.21
9.71
115.39
PB Ratio 1.85
MYGN's PB Ratio is ranked higher than
82% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. MYGN: 1.85 )
Ranked among companies with meaningful PB Ratio only.
MYGN' s PB Ratio Range Over the Past 10 Years
Min: 1.46  Med: 3.62 Max: 8.23
Current: 1.85
1.46
8.23
PS Ratio 1.87
MYGN's PS Ratio is ranked higher than
76% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. MYGN: 1.87 )
Ranked among companies with meaningful PS Ratio only.
MYGN' s PS Ratio Range Over the Past 10 Years
Min: 1.48  Med: 4.46 Max: 14.75
Current: 1.87
1.48
14.75
Price-to-Free-Cash-Flow 14.18
MYGN's Price-to-Free-Cash-Flow is ranked higher than
80% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. MYGN: 14.18 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MYGN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.6  Med: 16.28 Max: 44.47
Current: 14.18
7.6
44.47
Price-to-Operating-Cash-Flow 13.19
MYGN's Price-to-Operating-Cash-Flow is ranked higher than
72% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. MYGN: 13.19 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MYGN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.21  Med: 15.3 Max: 44
Current: 13.19
7.21
44
EV-to-EBIT 21.11
MYGN's EV-to-EBIT is ranked higher than
81% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. MYGN: 21.11 )
Ranked among companies with meaningful EV-to-EBIT only.
MYGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -102.5  Med: 10.3 Max: 52.4
Current: 21.11
-102.5
52.4
EV-to-EBITDA 12.88
MYGN's EV-to-EBITDA is ranked higher than
82% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. MYGN: 12.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -161.3  Med: 9.6 Max: 45.9
Current: 12.88
-161.3
45.9
PEG Ratio 7.27
MYGN's PEG Ratio is ranked lower than
53% of the 43 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.96 vs. MYGN: 7.27 )
Ranked among companies with meaningful PEG Ratio only.
MYGN' s PEG Ratio Range Over the Past 10 Years
Min: 0.44  Med: 1.11 Max: 6.27
Current: 7.27
0.44
6.27
Shiller PE Ratio 15.63
MYGN's Shiller PE Ratio is ranked higher than
90% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. MYGN: 15.63 )
Ranked among companies with meaningful Shiller PE Ratio only.
MYGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 12.14  Med: 46.04 Max: 2553
Current: 15.63
12.14
2553
Current Ratio 1.57
MYGN's Current Ratio is ranked higher than
69% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. MYGN: 1.57 )
Ranked among companies with meaningful Current Ratio only.
MYGN' s Current Ratio Range Over the Past 10 Years
Min: 1.17  Med: 5.81 Max: 20.28
Current: 1.57
1.17
20.28
Quick Ratio 1.36
MYGN's Quick Ratio is ranked higher than
68% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. MYGN: 1.36 )
Ranked among companies with meaningful Quick Ratio only.
MYGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.98  Med: 5.81 Max: 20.28
Current: 1.36
0.98
20.28
Days Inventory 93.55
MYGN's Days Inventory is ranked lower than
51% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. MYGN: 93.55 )
Ranked among companies with meaningful Days Inventory only.
MYGN' s Days Inventory Range Over the Past 10 Years
Min: 22.14  Med: 48.49 Max: 73.56
Current: 93.55
22.14
73.56
Days Sales Outstanding 55.33
MYGN's Days Sales Outstanding is ranked higher than
65% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. MYGN: 55.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.41  Med: 46.88 Max: 72.25
Current: 55.33
38.41
72.25
Days Payable 57.98
MYGN's Days Payable is ranked lower than
53% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. MYGN: 57.98 )
Ranked among companies with meaningful Days Payable only.
MYGN' s Days Payable Range Over the Past 10 Years
Min: 48.96  Med: 80.13 Max: 280.85
Current: 57.98
48.96
280.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 5.00
MYGN's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. MYGN: 5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.6  Med: -6.15 Max: 5.9
Current: 5
-13.6
5.9

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.60
MYGN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
96% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. MYGN: 0.60 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MYGN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.47  Med: 1.13 Max: 23.09
Current: 0.6
0.47
23.09
Price-to-Median-PS-Value 0.42
MYGN's Price-to-Median-PS-Value is ranked higher than
89% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. MYGN: 0.42 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MYGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35  Med: 1.49 Max: 10.22
Current: 0.42
0.35
10.22
Earnings Yield (Greenblatt) % 4.74
MYGN's Earnings Yield (Greenblatt) % is ranked higher than
88% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. MYGN: 4.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MYGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.9  Med: 8.7 Max: 22.7
Current: 4.74
1.9
22.7
Forward Rate of Return (Yacktman) % 4.48
MYGN's Forward Rate of Return (Yacktman) % is ranked higher than
51% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. MYGN: 4.48 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MYGN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -19.9  Med: 3.7 Max: 29.8
Current: 4.48
-19.9
29.8

More Statistics

Revenue (TTM) (Mil) $757.3
EPS (TTM) $ 0.45
Beta0.11
Short Percentage of Float49.64%
52-Week Range $15.15 - 35.35
Shares Outstanding (Mil)68.09

Analyst Estimate

Jun17 Jun18 Jun19 Jun20
Revenue (Mil $) 761 779 793 898
EPS ($) 1.07 1.08 1.07 1.36
EPS without NRI ($) 1.07 1.08 1.07 1.36
EPS Growth Rate
(Future 3Y To 5Y Estimate)
0.81%
Dividends per Share ($)
» More Articles for MYGN

Headlines

Articles On GuruFocus.com
Medicare Coverage of Prolaris® Test Expands with the Addition of Men Diagnosed with Favorable Int May 25 2017 
Myriad Genetics’ Prolaris® Test Accurately Predicts the 10-Year Risk of Metastases in Men Tr May 12 2017 
Myriad Genetics to Present Results from Four Studies at the American Urological Association 2017 An May 05 2017 
Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test Apr 27 2017 
Myriad to Announce Fiscal Third-Quarter 2017 Financial Results on May 2, 2017 Apr 18 2017 
Study Finds Wide Gap in Quality of BRCA1/2 Variant Classification Between Myriad Genetics and A Comm Apr 17 2017 
7 of the Worst-Performing Stocks in Gurus' Portfolios Apr 07 2017 
Myriad Genetics and BeiGene Sign Agreement to Develop Companion Diagnostics for Use with BeiGene†Apr 06 2017 
Pivotal Study Results for Myriad’s myPath® Melanoma Test Highlighted In Two Additional Scie Apr 05 2017 
Myriad Genetics Announces Five Scientific Presentations at the 2017 American College of Medical Gene Mar 20 2017 

More From Other Websites
Medicare Coverage of Prolaris® Test Expands with the Addition of Men Diagnosed with Favorable... May 25 2017
Edited Transcript of MYGN earnings conference call or presentation 2-May-17 8:30pm GMT May 23 2017
ETFs with exposure to Myriad Genetics, Inc. : May 22, 2017 May 22 2017
Myriad Genetics to Present Seven Studies at the 2017 American Society of Clinical Oncology Annual... May 18 2017
Myriad Genetics’ Prolaris® Test Accurately Predicts the 10-Year Risk of Metastases in Men Treated... May 12 2017
Myriad Genetics, Inc. :MYGN-US: Earnings Analysis: Q3, 2017 By the Numbers : May 8, 2017 May 08 2017
Don’t Give Up on Buybacks Just Yet May 07 2017
Myriad Genetics to Present Results from Four Studies at the American Urological Association 2017... May 05 2017
Myriad Genetics, Inc. breached its 50 day moving average in a Bullish Manner : MYGN-US : May 4, 2017 May 04 2017
Here's Why Myriad Genetics Rose as Much as 16% This Morning May 03 2017
Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma May 03 2017
Myriad Genetics (MYGN) Tops Q3 Earnings & Sales, Tweaks View May 03 2017
Myriad tops Street 3Q forecasts May 02 2017
Myriad Genetics shares jump on earnings beat, outlook May 02 2017
Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test... Apr 27 2017
Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings? Apr 24 2017
Myriad to Announce Fiscal Third-Quarter 2017 Financial Results on May 2, 2017 Apr 18 2017
Myriad Genetics, Inc. – Value Analysis (NASDAQ:MYGN) : April 17, 2017 Apr 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)